RY 144.17 0.4529% TD 77.39 0.0517% SHOP 78.87 -1.3878% CNR 171.64 0.5625% ENB 50.09 -0.4769% CP 110.62 0.6277% BMO 128.85 -0.548% TRI 233.58 1.1563% CNQ 103.29 -0.174% BN 60.87 -0.2295% ATD 75.6 -1.447% CSU 3697.0 1.1582% BNS 65.76 -0.3485% CM 66.6 -0.5525% SU 54.21 1.1569% TRP 53.15 0.3398% NGT 58.54 -0.3405% WCN 226.5 0.4123% MFC 35.905 0.9986% BCE 46.75 -0.5954%
Last update at 2024-05-16T19:32:00Z
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -18.97100M | -43.96000M | 6.69M | 32.09M | 22.78M |
| Minority interest | - | - | 0.00000M | 10.31M | 104.38M |
| Net income | -7.69700M | -29.89200M | 15.68M | 31.76M | 14.52M |
| Selling general administrative | 89.51M | 40.15M | 37.16M | 38.84M | 24.46M |
| Selling and marketing expenses | - | 48.47M | 37.22M | 35.59M | 7.79M |
| Gross profit | 155.32M | 138.06M | 115.41M | 81.69M | 26.92M |
| Reconciled depreciation | 59.13M | 62.62M | 47.91M | 32.08M | 4.27M |
| Ebit | - | -2.40300M | -5.32200M | -3.43700M | 13.99M |
| Ebitda | - | 60.22M | 42.59M | 28.64M | 18.26M |
| Depreciation and amortization | - | 62.62M | 47.91M | 32.08M | 4.27M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -2.69300M | -2.40300M | -5.32200M | -3.43700M | 13.99M |
| Other operating expenses | - | 310.62M | 256.31M | 229.52M | 60.12M |
| Interest expense | 10.69M | 6.60M | 3.62M | 3.40M | 1.01M |
| Tax provision | -11.27400M | -14.06800M | -8.98500M | 0.33M | 4.75M |
| Interest income | 13.76M | 15.76M | 14.04M | 14.32M | 32.88M |
| Net interest income | 3.07M | 4.03M | 3.76M | 10.92M | 22.53M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -14.06800M | -8.98500M | 0.33M | 4.75M |
| Total revenue | 335.66M | 293.56M | 243.48M | 199.52M | 47.46M |
| Total operating expenses | 338.35M | 155.12M | 128.24M | 111.69M | 39.58M |
| Cost of revenue | 180.33M | 155.50M | 128.07M | 117.83M | 20.54M |
| Total other income expense net | -19.34400M | -41.55700M | 12.01M | 35.52M | 8.80M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -7.69700M | -29.89200M | 15.68M | 31.76M | 18.03M |
| Net income applicable to common shares | - | -29.89200M | 15.68M | 42.07M | 14.52M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1054.84M | 991.89M | 1039.68M | 1305.30M | 1051.83M |
| Intangible assets | 338.78M | 350.30M | 156.55M | 173.37M | 17.48M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.70M | 4.51M | 4.75M | 85.01M | 1.04M |
| Total liab | 228.98M | 149.87M | 153.44M | 390.20M | 21.80M |
| Total stockholder equity | 825.86M | 842.02M | 886.24M | 810.73M | 1030.03M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 15.01M | 11.72M | 15.90M | 225.63M | 5.54M |
| Common stock | 599.05M | 628.85M | 694.35M | 723.83M | 761.84M |
| Capital stock | 599.05M | 628.85M | 694.35M | 723.83M | 761.84M |
| Retained earnings | 161.75M | 191.65M | 174.54M | 52.25M | 232.12M |
| Other liab | - | 31.89M | 36.83M | 29.56M | 4.62M |
| Good will | 82.27M | 75.40M | 77.72M | 88.26M | - |
| Other assets | 15.60M | 57.05M | 75.49M | 151.97M | 48.11M |
| Cash | 71.68M | 85.96M | 229.59M | 169.27M | 244.78M |
| Cash and equivalents | 0.30M | 9.03M | 2.58M | 5.34M | 0.00000M |
| Total current liabilities | 141.32M | 105.30M | 114.06M | 350.80M | 17.18M |
| Current deferred revenue | - | - | 14.61M | 39.85M | 0.18M |
| Net debt | 6.02M | -45.00500M | -173.40400M | -107.08900M | -244.78500M |
| Short term debt | 20.25M | 28.28M | 53.65M | 52.34M | 459.03M |
| Short long term debt | 17.67M | 26.66M | 51.77M | 50.56M | - |
| Short long term debt total | 77.70M | 40.96M | 56.19M | 62.18M | - |
| Other stockholder equity | 23.78M | 21.89M | 18.85M | 17.25M | 15.11M |
| Property plant equipment | 22.63M | 29.94M | 26.16M | 29.05M | 0.79M |
| Total current assets | 395.62M | 307.32M | 554.64M | 698.22M | 717.53M |
| Long term investments | 158.02M | 178.95M | 174.84M | 259.72M | 289.73M |
| Net tangible assets | - | 416.32M | 651.97M | 549.10M | 1012.56M |
| Short term investments | 119.54M | 77.03M | 181.75M | 261.35M | 459.03M |
| Net receivables | 110.20M | 67.41M | 82.04M | 111.73M | 3.00M |
| Long term debt | 52.40M | 9.27M | 0.00000M | 5.02M | - |
| Inventory | 92.49M | 72.40M | 56.51M | 70.87M | 1.14M |
| Accounts payable | 106.06M | 65.31M | 44.51M | 72.83M | 0.75M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 41.27M | -0.37600M | -1.50300M | 17.41M | 20.95M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 694.35M | 723.83M | 761.84M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 48.20M | 47.93M | 47.33M | 52.69M | 23.34M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 659.22M | 684.57M | 485.04M | 607.08M | 334.30M |
| Capital lease obligations | 7.63M | 5.03M | 4.42M | 6.60M | - |
| Long term debt total | 57.45M | 12.68M | 2.54M | 9.83M | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -33.78200M | -63.07900M | 85.29M | 263.31M | -11.86000M |
| Change to liabilities | - | 0.00000M | 11.46M | -46.85600M | 10.68M |
| Total cashflows from investing activities | - | -63.07900M | -105.27900M | 101.35M | -11.86000M |
| Net borrowings | - | - | -14.19200M | 6.73M | -8.61200M |
| Total cash from financing activities | -12.81300M | 1.76M | -78.31000M | -29.23300M | -62.79500M |
| Change to operating activities | - | -5.41300M | 2.00M | -2.60900M | -22.75300M |
| Net income | -7.69700M | -29.89200M | 15.68M | 31.76M | 18.03M |
| Change in cash | -26.48000M | -14.28400M | -143.62900M | 55.32M | -70.51700M |
| Begin period cash flow | 101.82M | 85.96M | 229.59M | 174.27M | 244.78M |
| End period cash flow | 75.34M | 71.68M | 85.96M | 229.59M | 174.27M |
| Total cash from operating activities | 20.11M | 40.48M | 44.62M | -12.20500M | 4.60M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 59.13M | 62.62M | 47.91M | 32.08M | 4.27M |
| Other cashflows from investing activities | - | -37.26300M | 30.93M | 29.13M | 14.64M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -27.09000M | -11.42800M | -17.18800M | 9.71M | 8.15M |
| Change to account receivables | 3.05M | -26.41800M | 8.59M | 20.11M | -10.40300M |
| Sale purchase of stock | -43.08000M | -30.06900M | -64.41500M | -36.78700M | -54.83800M |
| Other cashflows from financing activities | - | 52.12M | 9.72M | 25.41M | 0.66M |
| Change to netincome | - | 17.74M | -16.96300M | -64.74000M | -1.99200M |
| Capital expenditures | 14.89M | 25.82M | 224.18M | 20.67M | 2.95M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -34.84300M | -9.98900M | 0.63M | -21.60700M | -12.19900M |
| Stock based compensation | 2.36M | 1.89M | 3.04M | 1.95M | 2.14M |
| Other non cash items | 0.63M | 32.98M | -15.00800M | -54.37100M | -8.55800M |
| Free cash flow | 5.23M | 14.66M | -179.56500M | -32.87300M | 1.65M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GUD Knight Therapeutics Inc |
0.07 1.07% | 6.17 | - | 69.44 | 1.78 | 0.73 | 1.48 | 9.75 |
| BHC Bausch Health Companies Inc |
-0.09 0.92% | 9.65 | - | 2.10 | 0.47 | 18.74 | 3.89 | 18.18 |
| TLRY Tilray Inc |
0.14 4.98% | 2.95 | - | 1000.00 | 2.91 | 0.45 | 3.43 | -1.9457 |
| CRON Cronos Group Inc |
0.23 5.82% | 4.18 | - | - | 11.24 | 0.67 | 0.07 | 1.02 |
| TSND TerrAscend Corp. |
0.12 5.11% | 2.47 | - | - | - | - |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
3400 De Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA | Exec. Chairman | 1969 |
| Ms. Samira Sakhia BCom, CA, CPA, MBA | Pres, CEO & Director | 1968 |
| Mr. Arvind Utchanah | Chief Financial Officer | NA |
| Ms. Amal Khouri B.Sc., M.B.A. | Chief Bus. Officer | NA |
| Mr. Jeff Martens | Global VP Commercial | NA |
| Mr. Leopoldo Bosano | Vice-Pres of Manufacturing & Operations | NA |
| Ms. Daniela Marino | Global VP of Legal & Compliance | NA |
| Ms. Susan Caroline Emblem | Global VP of HR | NA |
| Ms. Jody Engel | Sr. Director of Bus. Devel. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
CA 
AU
UK
US
NZ
Please wait processing your request...